[1] Ahmad F, Nathani R, Venkat J, et al.  Molecular evaluation of BRAF gene mutation in thyroid tumors: significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease[J]. Exp Mol Pathol, 2018, 105(3): 380-386.   doi: 10.1016/j.yexmp.2018.11.002
[2]

赵海月. 甲状腺癌BRAFV600E基因突变与肿瘤侵袭、转移关键基因表达的研究[D]. 吉林: 吉林大学, 2018.

Zhao HY. Study on the mutation of BRAFV600E gene in thyroid carcinoma and the expression of key genes in tumor invasion and metastasis[D]. Jilin: Jilin University, 2018.
[3] 王欣怡, 白俊文.  甲状腺癌的相关基因BRAF、RET、RAS研究新进展[J]. 重庆医学, 2018, 47(36): 4631-4634.   doi: 10.3969/j.issn.1671-8348.2018.36.017
Wang XY, Bai JW.  New progress in the research of thyroid cancer related genes BRAF, RET and RAS[J]. Chongqing Med, 2018, 47(36): 4631-4634.   doi: 10.3969/j.issn.1671-8348.2018.36.017
[4] Pellegriti G, Frasca F, Regalbuto C, et al.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J]. J Cancer Epidemiol, 2013, 2013: 1-10.   doi: 10.1155/2013/965212
[5] Song YS, Lim JA, Choi H, et al.  Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients[J]. Cancer, 2016, 122(9): 1370-1379.   doi: 10.1002/cncr.29934
[6] Soares P, Lima J, Preto A, et al.  Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas[J]. Curr Genomics, 2011, 12(8): 609-617.   doi: 10.2174/138920211798120853
[7] Nikiforov YE, Nikiforova MN.  Molecular genetics and diagnosis of thyroid cancer[J]. Nat Rev Endocrinol, 2011, 7(10): 569-580.   doi: 10.1038/nrendo.2011.142
[8] Kogai T, Brent GA.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics[J]. Pharmacol Ther, 2012, 135(3): 355-370.   doi: 10.1016/j.pharmthera.2012.06.007
[9]

Kowalik A, Kowalska A, Walczyk A, et al. Evaluation of molecular diagnostic approaches for the detection of BRAF p. V600E mutations in papillary thyroid cancer: clinical implications[J/OL]. PLoS One, 2017, 12(6): e179691[2019-09-15]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179691. DOI: 10.1371/journal.pone.0179691.
[10] Conzo G, Pasquali D, Bellastella G, et al.  Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases[J]. Endocrine, 2013, 44(2): 419-425.   doi: 10.1007/s12020-013-9877-2
[11] Lan XB, Sun W, Zhang H, et al.  A meta-analysis of central lymph node metastasis for predicting lateral involvement in papillary thyroid carcinoma[J]. Otolaryngol Head Neck Surg, 2015, 153(5): 731-738.   doi: 10.1177/0194599815601412
[12] Gouveia C, Can NT, Bostrom A, et al.  Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma[J]. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170.   doi: 10.1001/jamaoto.2013.4501
[13] Dong SY, Zeng RC, Jin LP, et al.  BRAFV600E mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: different histological subtypes and preoperative lymph node status should be taken into account[J]. Oncol Lett, 2017, 14(4): 4122-4134.   doi: 10.3892/ol.2017.6694
[14] Chen J, Li XL, Zhao CK, et al.  Conventional ultrasound, immunohistochemical factors and BRAFV600E mutation in predicting central cervical lymph node metastasis of papillary thyroid carcinoma[J]. Ultrasound Med Biol, 2018, 44(11): 2296-2306.   doi: 10.1016/j.ultrasmedbio.2018.06.020
[15] Tufano RP, Teixeira GV, Bishop J, et al.  BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5): 274-286.   doi: 10.1097/MD.0b013e31826a9c71
[16] Song JY, Sun SR, Dong F, et al.  Predictive value of BRAFV600E mutation for lymph node metastasis in papillary thyroid cancer: a meta-analysis[J]. Curr Med Sci, 2018, 38(5): 785-797.   doi: 10.1007/s11596-018-1945-7
[17] Scott E, Learoyd D, Clifton-Bligh RJ.  Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives[J]. Future Oncol, 2016, 12(22): 2603-2613.   doi: 10.2217/fon-2016-0171
[18] Namba H, Nakashima M, Hayashi T, et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers[J]. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397.   doi: 10.1210/jc.2003-030305
[19] Melo M, da Rocha AG, Batista R, et al.  TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease[J]. J Clin Endocrinol Metab, 2017, 102(6): 1898-1907.   doi: 10.1210/jc.2016-2785
[20] Vuong HG, Altibi AM, Duong UN, et al.  Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations a meta-analysis[J]. Tumor Biol, 2017, 39(10): 568834305-.   doi: 10.1177/1010428317713913
[21]

Ge JS, Wang J, Wang H, et al. The BRAFV600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer[J/OL]. J Cancer, 2020, 11(4): 932−939[2019-09-15]. https://www.jcancer.org/v11p0932.htm. DOI: 10.7150/jca.33105.
[22] Durante C, Puxeddu E, Ferretti E, et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism[J]. J Clin Endocrinol Metab, 2007, 92(7): 2840-2843.   doi: 10.1210/jc.2006-2707
[23] Mian C, Barollo S, Pennelli G, et al.  Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake[J]. Clin Endocrinol (Oxf), 2008, 68(1): 108-116.   doi: 10.1111/j.1365-2265.2007.03008.x
[24] Yang K, Wang H, Liang Z, et al.  BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma[J]. Clin Nucl Med, 2014, 39(8): 675-679.   doi: 10.1097/RLU.0000000000000498
[25] Anastas JN, Moon RT.  WNT signalling pathways as therapeutic targets in cancer[J]. Nat Rev Cancer, 2013, 13(1): 11-26.   doi: 10.1038/nrc3419
[26] Kim TH, Park YJ, Lim JA, et al.  The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis[J]. Cancer, 2012, 118(7): 1764-1773.   doi: 10.1002/cncr.26500
[27] Li F, Chen GQ, Sheng CJ, et al.  BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis[J]. Endocr Relat Cancer, 2015, 22(2): 159-168.   doi: 10.1530/ERC-14-0531
[28]

Liu S, Zhang BF, Zhao YR, et al. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population[J/OL]. Int J Clin Exp Pathol, 2014, 7(10): 6922−6928[2019-09-15]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230084.
[29] Li C, Lee KC, Schneider EB, et al.  BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(12): 4559-4570.   doi: 10.1210/jc.2012-2104
[30]

Zhu GQ, Deng YY, Pan LQ, et al. Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy[J]. Endocr Connect, 2019, 8(6): 754−763[2019-09-15]. https://ec.bioscientifica.com/view/journals/ec/8/6/EC-19-0045.xml. DOI: 10.1530/EC-19-0045.
[31] 杨敬, 严淑萍, 龚艳萍, 等.  BRAFV600E基因突变与中国甲状腺乳头状癌患者临床病理学特征间关系的Meta分析[J]. 华西医学, 2016, 31(3): 467-479.   doi: 10.7507/1002-0179.201600127
Yang J, Yan SP, Gong YP, et al.  The association between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid carcinoma in chinese population: a meta-analysis[J]. West China Med J, 2016, 31(3): 467-479.   doi: 10.7507/1002-0179.201600127
[32]

Liu CP, Chen TW, Liu Z. Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis[J]. World J Surg Oncol, 2016, 14(1): 241[2019-09-15]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012084. DOI: 10.1186/s12957-016-0979-1.
[33] Pelttari H, Schalin-Jäntti C, Arola J, et al.  BRAFV600E mutation does not predict recurrence after long-term follow-up in TNM stage Ⅰ or Ⅱ papillary thyroid carcinoma patients[J]. APMIS, 2012, 120(5): 380-386.   doi: 10.1111/j.1600-0463.2011.02844.x
[34] Xing MZ, Alzahrani AS, Carson KA, et al.  Association between BRAFV600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1): 42-50.   doi: 10.1200/JCO.2014.56.8253
[35] Landa I, Ibrahimpasic T, Boucai L, et al.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest, 2016, 126(3): 1052-1066.   doi: 10.1172/JCI85271
[36] Yang J, Gong YP, Yan SP, et al.  Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis[J]. Endocrine, 2020, 67(1): 44-57.   doi: 10.1007/s12020-019-02117-2
[37] Xing MZ, Liu RY, Liu XL, et al.  BRAFV600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J]. J Clin Oncol, 2014, 32(25): 2718-2726.   doi: 10.1200/JCO.2014.55.5094
[38]

Rusinek D, Pfeifer A, Krajewska J, et al. Coexistence of TERT promoter mutations and the BRAFV600E alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of polish patients[J]. Int J Mol Sci, 2018, 19(9): 2647[2019-09-15]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163174. DOI: 10.3390/ijms19092647.
[39] Trybek T, Walczyk A, Gąsior-Perczak D, et al.  Impact of BRAFV600E and TERT promoter mutations on response to therapy in papillary thyroid cancer[J]. Endocrinology, 2019, 160(10): 2328-2338.   doi: 10.1210/en.2019-00315
[40] Vuong HG, Altibi AMA, Duong UNP, et al.  Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis[J]. Clin Endocrinol (Oxf), 2017, 87(5): 411-417.   doi: 10.1111/cen.13413
[41] 王源波, 贾茜, 鲁雪妮, 等.  中高危分化型甲状腺癌患者131碘治疗前刺激性甲状腺球蛋白与治疗后临床转归的相关性[J]. 西安交通大学学报: 医学版, 2019, 40(3): 437-441.   doi: 10.7652/jdyxb201903018
Wang YB, Jia Q, Lu XN.  Correlation between the 131 iodine stimulated thyroglobulin before treatment and 131 iodine treatment in patients with high-risk differentiated thyroid carcinoma[J]. J Xi'an Jiaotong Univ (Med Sci), 2019, 40(3): 437-441.   doi: 10.7652/jdyxb201903018